Targeting the transferrin receptor for brain drug delivery
Obtaining efficient drug delivery to the brain remains the biggest challenge for the
development of therapeutics to treat diseases of the central nervous system. The main …
development of therapeutics to treat diseases of the central nervous system. The main …
[HTML][HTML] Engineered antibodies: new possibilities for brain PET?
Almost 50 million people worldwide are affected by Alzheimer's disease (AD), the most
common neurodegenerative disorder. Development of disease-modifying therapies would …
common neurodegenerative disorder. Development of disease-modifying therapies would …
[HTML][HTML] In vivo imaging of alpha-synuclein with antibody-based PET
S Roshanbin, M Xiong, G Hultqvist, L Söderberg… - …, 2022 - Elsevier
The protein alpha-synuclein (αSYN) plays a central role in synucleinopathies such as
Parkinsons's disease (PD) and multiple system atrophy (MSA). Presently, there are no …
Parkinsons's disease (PD) and multiple system atrophy (MSA). Presently, there are no …
[HTML][HTML] Brain pharmacokinetics of two BBB penetrating bispecific antibodies of different size
Abstract Background Transferrin receptor (TfR1) mediated enhanced brain delivery of
antibodies have been studied extensively in preclinical settings. However, the brain …
antibodies have been studied extensively in preclinical settings. However, the brain …
Brain delivery of biologics using a cross-species reactive transferrin receptor 1 VNAR shuttle.
Abstract Transferrin receptor 1 (TfR1) mediated transcytosis is an attractive strategy to
enhance brain uptake of protein drugs, but translation remains a challenge. Here, a single …
enhance brain uptake of protein drugs, but translation remains a challenge. Here, a single …
[HTML][HTML] Focused ultrasound for opening blood-brain barrier and drug delivery monitored with positron emission tomography
Focused ultrasound (FUS) is a minimally-invasive technology used for treatment of many
diseases, including diseases related to the colon, uterus, prostate, and brain. Although it has …
diseases, including diseases related to the colon, uterus, prostate, and brain. Although it has …
[HTML][HTML] Identification and in vivo characterization of a brain-penetrating nanobody
Y Wouters, T Jaspers, B De Strooper… - Fluids and Barriers of the …, 2020 - Springer
Background Preclinical models to determine blood to brain transport ability of therapeutics
are often ambiguous. In this study a method is developed that relies on CNS target …
are often ambiguous. In this study a method is developed that relies on CNS target …
Light-controlled fluorescent probes for precisely monitoring brain amyloid-β aggregates in Alzheimer's disease
Y Gu, Z Ding, C Zheng, Y Xu, T Liu, C Mao… - Chemical Engineering …, 2022 - Elsevier
Alzheimer's disease (AD) is a neurodegenerative disorder in which the biological fate of
amyloid-beta (Aβ) aggregates is a fundamental question. Fluorescent probes as one of the …
amyloid-beta (Aβ) aggregates is a fundamental question. Fluorescent probes as one of the …
[HTML][HTML] SPECT imaging of distribution and retention of a brain-penetrating bispecific amyloid-β antibody in a mouse model of Alzheimer's disease
Background Alzheimer's disease (AD) immunotherapy with antibodies targeting amyloid-β
(Aβ) has been extensively explored in clinical trials. The aim of this study was to study the …
(Aβ) has been extensively explored in clinical trials. The aim of this study was to study the …
[HTML][HTML] ImmunoPET imaging of amyloid-beta in a rat model of Alzheimer's disease with a bispecific, brain-penetrating fusion protein
G Bonvicini, S Syvänen, KG Andersson… - Translational …, 2022 - Springer
Background Hijacking the transferrin receptor (TfR) is an effective strategy to transport
amyloid-beta (Aβ) immuno-positron emission tomography (immunoPET) ligands across the …
amyloid-beta (Aβ) immuno-positron emission tomography (immunoPET) ligands across the …